MX2010003987A - Inhibidores de cinasas de proteina. - Google Patents
Inhibidores de cinasas de proteina.Info
- Publication number
- MX2010003987A MX2010003987A MX2010003987A MX2010003987A MX2010003987A MX 2010003987 A MX2010003987 A MX 2010003987A MX 2010003987 A MX2010003987 A MX 2010003987A MX 2010003987 A MX2010003987 A MX 2010003987A MX 2010003987 A MX2010003987 A MX 2010003987A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- inhibitors
- protein kinases
- cyclin
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos de la fórmula general I, en donde R1, R2, R3, x, A y Ra son como se define en la presente invención son inhibidores de cinasas dependientes de ciclina y son útiles para prevenir y/o tratar cualquier tipo de dolor, trastornos inflamatorios, trastornos inmunológicos, enfermedades proliferativas, enfermedades infecciosas, enfermedades cardiovasculares y enfermedades neurodegenerativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99882107P | 2007-10-12 | 2007-10-12 | |
PCT/EP2008/063715 WO2009047359A1 (en) | 2007-10-12 | 2008-10-13 | Inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010003987A true MX2010003987A (es) | 2010-08-04 |
Family
ID=40227837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010003987A MX2010003987A (es) | 2007-10-12 | 2008-10-13 | Inhibidores de cinasas de proteina. |
Country Status (19)
Country | Link |
---|---|
US (2) | US8716296B2 (es) |
EP (1) | EP2212297B1 (es) |
JP (2) | JP5681855B2 (es) |
KR (1) | KR20100090772A (es) |
CN (2) | CN104151293A (es) |
AT (1) | ATE510827T1 (es) |
AU (1) | AU2008309517B2 (es) |
BR (1) | BRPI0818543A2 (es) |
CA (1) | CA2702008A1 (es) |
DK (1) | DK2212297T3 (es) |
EA (1) | EA020439B1 (es) |
HK (2) | HK1150052A1 (es) |
HR (1) | HRP20110470T1 (es) |
IL (1) | IL204594A (es) |
MX (1) | MX2010003987A (es) |
NZ (1) | NZ584454A (es) |
SI (1) | SI2212297T1 (es) |
WO (1) | WO2009047359A1 (es) |
ZA (1) | ZA201001910B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011004494A (es) | 2008-10-31 | 2011-05-24 | Genentech Inc | Compuestos de pirazolopirimidina inhibidores de jak y metodos. |
JP2012508238A (ja) * | 2008-11-07 | 2012-04-05 | ハー・ルンドベック・アクチエゼルスカベット | 生物活性を有するアミド |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
US9155724B2 (en) | 2010-02-05 | 2015-10-13 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
NZ627520A (en) | 2010-03-10 | 2015-10-30 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
US9290499B2 (en) | 2010-05-19 | 2016-03-22 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
RU2604062C2 (ru) * | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 |
EP2668162A1 (en) * | 2011-01-28 | 2013-12-04 | Novartis AG | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
WO2012101064A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
EP2562265A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Susceptibility to selective CDK9 inhibitors |
RU2631655C2 (ru) | 2011-10-03 | 2017-09-26 | Зэ Юниверсити Оф Норд Каролина Эт Чапель Хилл | Пирролопиримидиновые соединения для лечения злокачественной опухоли |
WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
US8541577B2 (en) * | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
LT3527563T (lt) | 2013-03-12 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
CA2901334A1 (en) | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
AU2014244263A1 (en) | 2013-03-13 | 2015-08-13 | Abbvie Inc. | CDK9 kinase inhibitors |
MX2015012153A (es) | 2013-03-14 | 2015-12-01 | Abbvie Inc | Inhibidores de la quinasa pirrolopirimidina cdk9. |
BR112015023187A2 (pt) | 2013-03-14 | 2017-07-18 | Abbvie Inc | inibidores de pirrolo[2,3 - b] piridina cdk9 kinase |
TW201444836A (zh) | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并[2,3-b]吡啶cdk9激酶抑制劑 |
GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
US9328112B2 (en) | 2014-02-06 | 2016-05-03 | Abbvie Inc. | Tetracyclic CDK9 kinase inhibitors |
US20150291609A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrimidine compounds |
US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
WO2016061144A1 (en) | 2014-10-14 | 2016-04-21 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
WO2016058544A1 (en) * | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
ES2728356T3 (es) | 2015-06-29 | 2019-10-23 | Astrazeneca Ab | Derivados de amidas policíclicas como inhibidores de CDK9 |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
US10934272B2 (en) | 2016-04-07 | 2021-03-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pyridyl derivatives as bromodomain inhibitors |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
CA3040815C (en) * | 2016-10-20 | 2021-07-20 | Steven Martin Evans | Anti-proliferative agents for treating pah |
AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
UA125123C2 (uk) | 2017-05-18 | 2022-01-12 | Ідорсія Фармасьютікалз Лтд | Фенільні похідні як модулятори pge2 рецепторів |
AR111874A1 (es) | 2017-05-18 | 2019-08-28 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
CA3060394A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
WO2018215389A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018214867A1 (zh) * | 2017-05-24 | 2018-11-29 | 上海和誉生物医药科技有限公司 | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 |
US20230102081A1 (en) | 2019-12-09 | 2023-03-30 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound as cyclin-dependent kinase 9 inhibitor and use thereof |
RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
WO2022257965A1 (zh) * | 2021-06-09 | 2022-12-15 | 石药集团中奇制药技术(石家庄)有限公司 | 固体形式的周期蛋白依赖性激酶9抑制剂及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0108611A (pt) | 2000-02-25 | 2003-05-06 | Hoffmann La Roche | Moduladores de receptor de adenosina |
DE10114138C2 (de) | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO2002094825A1 (fr) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de spiropiperidine |
DE10129028A1 (de) | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
CA2519677A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
GB0315966D0 (en) | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
BRPI0412347A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
BRPI0412351A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | derivados e piridilamino-pirimidina como inibidores de proteìna quinase |
US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
WO2005040135A1 (ja) | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
AU2005236055B2 (en) | 2004-04-20 | 2011-10-06 | Transtech Pharma, Llc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
FR2878247B1 (fr) | 2004-11-19 | 2008-10-03 | Galderma Res & Dev | Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
WO2006125616A2 (en) * | 2005-05-25 | 2006-11-30 | Ingenium Pharmaceuticals Ag | Pyrimidine-based cdk inhibitors for treating pain |
-
2008
- 2008-10-13 BR BRPI0818543A patent/BRPI0818543A2/pt not_active IP Right Cessation
- 2008-10-13 AU AU2008309517A patent/AU2008309517B2/en not_active Ceased
- 2008-10-13 CA CA2702008A patent/CA2702008A1/en not_active Abandoned
- 2008-10-13 EP EP08838451A patent/EP2212297B1/en not_active Not-in-force
- 2008-10-13 EA EA201000554A patent/EA020439B1/ru not_active IP Right Cessation
- 2008-10-13 DK DK08838451.6T patent/DK2212297T3/da active
- 2008-10-13 CN CN201410394966.8A patent/CN104151293A/zh active Pending
- 2008-10-13 US US12/226,286 patent/US8716296B2/en not_active Expired - Fee Related
- 2008-10-13 NZ NZ584454A patent/NZ584454A/en not_active IP Right Cessation
- 2008-10-13 MX MX2010003987A patent/MX2010003987A/es active IP Right Grant
- 2008-10-13 WO PCT/EP2008/063715 patent/WO2009047359A1/en active Application Filing
- 2008-10-13 KR KR1020107010451A patent/KR20100090772A/ko not_active Application Discontinuation
- 2008-10-13 SI SI200830286T patent/SI2212297T1/sl unknown
- 2008-10-13 AT AT08838451T patent/ATE510827T1/de not_active IP Right Cessation
- 2008-10-13 CN CN200880119493.3A patent/CN101889004B/zh not_active Expired - Fee Related
- 2008-10-13 JP JP2010528428A patent/JP5681855B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-17 ZA ZA2010/01910A patent/ZA201001910B/en unknown
- 2010-03-18 IL IL204594A patent/IL204594A/en not_active IP Right Cessation
-
2011
- 2011-04-27 HK HK11104221.0A patent/HK1150052A1/xx not_active IP Right Cessation
- 2011-06-24 HR HR20110470T patent/HRP20110470T1/hr unknown
-
2014
- 2014-05-05 US US14/269,703 patent/US20150038516A1/en not_active Abandoned
- 2014-09-03 JP JP2014178745A patent/JP2015038077A/ja active Pending
-
2015
- 2015-05-13 HK HK15104540.0A patent/HK1203950A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20100090772A (ko) | 2010-08-17 |
AU2008309517B2 (en) | 2013-03-14 |
IL204594A (en) | 2013-12-31 |
US20100249149A1 (en) | 2010-09-30 |
EA201000554A1 (ru) | 2011-04-29 |
SI2212297T1 (sl) | 2011-09-30 |
BRPI0818543A2 (pt) | 2018-10-23 |
CN101889004A (zh) | 2010-11-17 |
HRP20110470T1 (hr) | 2011-07-31 |
ATE510827T1 (de) | 2011-06-15 |
NZ584454A (en) | 2011-09-30 |
IL204594A0 (en) | 2010-11-30 |
ZA201001910B (en) | 2011-05-25 |
CN104151293A (zh) | 2014-11-19 |
EP2212297A1 (en) | 2010-08-04 |
US8716296B2 (en) | 2014-05-06 |
HK1150052A1 (en) | 2011-10-28 |
EA020439B1 (ru) | 2014-11-28 |
WO2009047359A1 (en) | 2009-04-16 |
JP5681855B2 (ja) | 2015-03-11 |
JP2015038077A (ja) | 2015-02-26 |
AU2008309517A1 (en) | 2009-04-16 |
DK2212297T3 (da) | 2011-09-05 |
CA2702008A1 (en) | 2009-04-16 |
CN101889004B (zh) | 2014-09-10 |
EP2212297B1 (en) | 2011-05-25 |
HK1203950A1 (en) | 2015-11-06 |
US20150038516A1 (en) | 2015-02-05 |
JP2011500539A (ja) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203950A1 (en) | Inhibitors of protein kinases | |
WO2009011850A3 (en) | Novel therapeutic compounds | |
EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
MX2012002542A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina. | |
UA104731C2 (ru) | Ингибиторы р38 мар-киназ | |
MX364157B (es) | Compuestos de pirazolo [1,5-a] pirimidina sustituidos como inhibidores de trk cinasa. | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
MY159230A (en) | P38 map kinase inhibitors | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
TN2011000293A1 (en) | Protein kinase inhibitors | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
EA200970738A1 (ru) | Ингибиторы активности akt | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
EA201201274A1 (ru) | Ингибиторы протеинкиназ | |
EA201170832A1 (ru) | Пуриновые соединения | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
EA201270535A1 (ru) | Пуриновые производные, применимые в качестве ингибиторов hsp90 | |
WO2010124121A8 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
JO2822B1 (en) | Inhibitors of the enzyme kinase P70 S6 and AKT | |
MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
ATE517873T1 (de) | 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |